Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Payables (2016 - 2025)

Acro Biomedical (ACBM) has 10 years of Payables data on record, last reported at $55550.0 in Q4 2025.

  • For Q4 2025, Payables fell 64.04% year-over-year to $55550.0; the TTM value through Dec 2025 reached $55550.0, down 64.04%, while the annual FY2025 figure was $55550.0, 64.04% down from the prior year.
  • Payables reached $55550.0 in Q4 2025 per ACBM's latest filing, down from $116582.0 in the prior quarter.
  • Across five years, Payables topped out at $155507.0 in Q3 2024 and bottomed at $12072.0 in Q2 2021.
  • Average Payables over 5 years is $91025.6, with a median of $95493.0 recorded in 2025.
  • Peak YoY movement for Payables: soared 1026.12% in 2021, then crashed 64.04% in 2025.
  • A 5-year view of Payables shows it stood at $26197.0 in 2021, then skyrocketed by 192.29% to $76571.0 in 2022, then skyrocketed by 101.7% to $154444.0 in 2023, then rose by 0.01% to $154460.0 in 2024, then plummeted by 64.04% to $55550.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $55550.0 in Q4 2025, $116582.0 in Q3 2025, and $95493.0 in Q2 2025.